BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Idecabtagene vicleucel readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Idecabtagene vicleucel\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05393804-3314@assetmemo.bio
DTSTAMP:20261121T005654Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Idecabtagene vicleucel: Phase 2 readout est. (NCT05393804)
DESCRIPTION:Idecabtagene vicleucel\, phase 2\, Multiple Myeloma.\nStudy: A 
 Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple My
 eloma Who Have Had a Hematopoietic Cell Transplant\nEstimated primary comp
 letion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ide
 cabtagene-vicleucel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05393804
URL:https://assetmemo.bio/drug/idecabtagene-vicleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
